

SUPPLEMENTARY DATA

Figure S1. Decision algorithm in Bicêtre Hospital, during the spring 2020 COVID-19 outbreak



COVIDOM is the French ambulatory follow-up health care program for patients with COVID-19; ICU: intensive care unit; SpO2: oxygen peripheral saturation while breathing room air; RR: respiratory rate; *COVID-19 was highly suspected if symptoms and/or CT-scan were typical; diagnosis was confirmed by positive RT-PCR. #List of risk factors: age > 65 years; obesity; chronic respiratory failure; heart failure; renal failure; cirrhosis; diabetes; immunosuppression/cancer; pregnancy.

Figure S2. Pneumonia severity according to ICS doses



ICS: inhaled corticosteroids

Table S1. Daily doses of asthma controller at admission

SABA alone	11 (30)
Salbutamol 100 μg p.r.n	9
Terbutaline 500 mg p.r.n	2
LTRA (GINA 2)	1 (2)
Montelukast, 10 mg	1
Medium dose ICS (GINA 2)	1 (2)
Non-extrafine particle beclometasone pMDI, 1000µg	1
Low-dose ICS/LABA (GINA 3)	5 (14)
Fluticasone furoate/vilanterol DPI, 92/22 µg	1
Budesonide/formoterol DPI, 400/12 μg	4
Medium-dose ICS/LABA (GINA 4)	8 (22)
Fluticasone proprionate/salmeterol	3
pMDI, 500/50 μg	1
DPI, 500/100 μg	2
Extrafine particle beclometasone/fomoterol	5
pMDI, 400/24 μg	4
Add-on montelukast, 10 mg	1
DPI, 400/12 μg	1
High-dose ICS/LABA (GINA 5)	11 (30)
Fluticasone proprionate/salmeterol	7
DPI, 1000/100 μg	5
Add-on tiotropium SMI, 5µg	1
DPI, 2000/200 μg	1
pMDI, 1000/100 μg	1
Extrafine particle beclometasone/fomoterol DPI, $800/24~\mu g$	1
Budesonide/formoterol DPI, 1600/48 μg	3
Add-on omalizumab, 300 mg twice monthly	2
Add-on oral CS, 5 mg daily	1

CS: corticosteroids; DPI: dry powder inhaler; LTRA: leukotriene receptor antagonist; pMDI: pressurized metered-dose inhaler; SABA: short-acting bronchodilators.